Drug Safety can Now be Tested With Near-Infrared Chemical Imaging

by Chrisy Ngilneii on March 13, 2018 at 8:29 PM
Drug Safety can Now be Tested With Near-Infrared Chemical Imaging

The potency and safety of drugs may be predicted with the help of near-infrared chemical imagine, recent research finds.


Process Analytical Technology (PAT) has been of great value to pharmaceutical manufacturing, enabling testing throughout the manufacturing process and allowing the real-time release of the finished product. Often, the final step in the production is tableting. In this, a die used to compress the tablet is filled with powder via a feed frame, that ensures a constant supply of material. The powder contains the active pharmaceutical ingredient (API) as well as other material required for the production of the tablet. Subject to the mechanical processes within the feed frame, the consistency of the powder varies due to density variations and segmentation. Such inconsistencies can lead to differences in concentrations of the API in individual tablets. Too much or too little API in a tablet are each dangerous for the patient taking the medicine.

These variations in powder flow phenomena in pharmaceutical manufacturing feed frames have previously been investigated with near-infrared (NIR) spectroscopy. However, whilst this has provided useful information, due to the comparatively small area analyzed with this technique, areas of segregation can be missed.

According to Ryan Gosselin, Associate Professor in the Department of Chemical Engineering and Biotechnology Engineering of the Université de Sherbrooke, Québec, Canada, "concentration predictions with NIR chemical imaging were found to be similar to those of the NIR spectroscopy model. However, NIR chemical imaging is better positioned to view concentration modifications over larger sample areas, and different image sections can be analyzed separately in the event of localized concentration changes."

Source: Eurekalert
Font : A-A+



Recommended Readings

Latest Drug News

Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Drug Safety can Now be Tested With Near-Infrared Chemical Imaging Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests